Endocuff With or Without AI-assisted Colonoscopy

Sponsor
The University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05133544
Collaborator
(none)
656
1
3
21.1
31.1

Study Details

Study Description

Brief Summary

Colonoscopy is considered the gold standard for diagnosis of colonic polyps. However, it was reported that colonoscopy could still miss colonic polyps. Many attempts have been made to improve the detection rate of colonoscopy. Artificial intelligence (AI) is a promising new technique to improve detection rate of colonic adenoma. However, it remains uncertain whether whether the combined use of Endocuff and AI assisted examination could help to further improve the adenoma detection rate. This is a prospective randomized trial comparing the use of endocuff with AI, AI alone or conventional colonoscopy examination on adenoma detection rate.

Condition or Disease Intervention/Treatment Phase
  • Device: Endocuff with AI
  • Device: AI alone
N/A

Detailed Description

TThis is a prospective randomized tandem colonoscopy trial comparing three different modes of colonoscopy techniques. The first group will use Endocuff (Olympus, Hong Kong) and AI assisted colonoscopy. The second group will use AI assisted colonoscopy alone and the third group will use standard high-definition white light colonoscopy.

Eligible patients will be randomly allocated in a 1:1:1 ratio to three groups. Patients will be stratified according to indications of colonoscopy (symptomatic vs screening/surveillance).

All examination will be performed with high-definition endoscopes (EVIS-EXERA 290 video system, Olympus Optical, Tokyo, Japan) under white light by experienced endoscopists. All endoscopists should have received training on the interpretation of real-time AI detection system as well as the Endocuff before performing study colonoscopy.

In all colonoscopy examination, colonoscope will be first advanced to the cecum as confirmed by identification of the appendiceal orifice and ileocecal valve or by intubation of the ileum. After cecal intubation is performed, the colonoscopy is first withdrawn according to the group assigned. For group 1, the first withdrawal would be done with Endocuff and AI assistance. For group 2, the first withdrawal would be done under AI assistance only. For group 3, the first withdrawal would be done under standard high definition colonoscopy only.

All detected polyps will be removed during the withdrawal only. The size (measured with biopsy forceps), location and morphology of each polyp will be recorded by an independent observer. The withdrawal time (minus the polypectomy site) will be measured by a stopwatch and with a minimum of 6 minutes. The bowel preparation quality will be graded according to the Boston Bowel Preparation Scale

Study Design

Study Type:
Interventional
Anticipated Enrollment :
656 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Endocuff With or Without Artificial Intelligence-assisted Colonoscopy in Detection of Colorectal Adenoma: a Randomized Colonoscopy Trial
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Endocuff- AI assisted colonoscopy

Endocuff (Olympus, Hong Kong) and AI assisted colonoscopy will be used

Device: Endocuff with AI
Use of endocuff with computer assisted polyp detection

Active Comparator: AI-assisted colonoscopy

AI assisted colonoscopy will be used

Device: AI alone
Use of computer assisted polyp detection

No Intervention: Conventional colonoscopy

Conventional colonoscopy will be used without AI or Endocuff.

Outcome Measures

Primary Outcome Measures

  1. Adenoma detection rate [One month after colonoscopy]

    The proportion of patients with at least one adenomas

Secondary Outcome Measures

  1. Polyp detection rate [One month after colonoscopy]

    the proportion of patients with at least one polyp

  2. Sessile serrated adenomas detection rate [One month after colonoscopy]

    The proportion of patients with at least one sessile serrated adenomas

  3. Sessile serrated polyps detection rate [One month after colonoscopy]

    The proportion of patients with at least one sessile serrated polyps

  4. Advanced adenoma detection rates [One month after colonoscopy]

    The proportion of patients with at least one advanced adenomas

  5. Mean number of polyp per patient [One month after colonoscopy]

    The mean number of polyp per patient

  6. Mean number of adenoma per patient [One month after colonoscopy]

    The mean number of adenoma per patient

  7. Total number of polyp or adenoma per patient. [One month after colonoscopy]

    The total number of polyp or adenoma per patient.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All adult patients, aged 40 or above, undergoing outpatient colonoscopy in the Queen Mary Hospital in Hong Kong will be recruited.
Exclusion Criteria:
  • Patients will be excluded if they have history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe. Moreover, after randomization, if the cecum could not be intubated for various reasons or Boston Bowel Preparation Scale (BBPS) score is <2, these patients will be excluded

Contacts and Locations

Locations

Site City State Country Postal Code
1 Queen Mary Hospital Hong Kong Hong Kong

Sponsors and Collaborators

  • The University of Hong Kong

Investigators

  • Study Director: Wai Keung Leung, MD, The University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Lui Ka-Luen, Honorary assistant Professor, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05133544
Other Study ID Numbers:
  • UW 20-647
First Posted:
Nov 24, 2021
Last Update Posted:
Jul 26, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Lui Ka-Luen, Honorary assistant Professor, The University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 26, 2022